Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma

Main Article Content

Oktay Unsal
Ozan Yazici
Nuriye Ozdemir
Ahmet Ozet

Abstract

Aim:  This study aimed to analyse the clinical characteristics, effectiveness and safety of nivolumab monotherapy in patients aged≥ 65 years with metastatic melanoma.


Materials and Methods: This study involved patients aged ≥65 years who were diagnosed with metastatic cutaneous or mucosal melanoma. Patients with BRAF wild type, ECOG performance status 0-1, and who had previously received one line of chemotherapy were included, irrespective of PD-L1 expression. The study analyzed PFS, OS, and adverse event profiles.


Results: Twenty-one patients, with a median age of 70, were analysed in the study. The median PFS for nivolumab as second-line therapy in elderly patients was 3.5 months (95% CI, 1.5 to 5.6 months), while the median OS was 14.5 months (95% CI, 10.3 to 18.6 months). The most common grade 1-2 adverse events were anemia (66.7%) and serum creatinine increase (23.8%). Additionally, the rate of grade 3-4 adverse events due to all causes was 28.6%. There was no grade 5 adverse event.


Conclusion: Nivolumab is effective and safe as second-line therapy in patients aged ≥65 years with metastatic melanoma. It is a tolerable and effective treatment choice for elderly patients who cannot received nivolumab in first line therapy.

Downloads

Download data is not yet available.

Article Details

How to Cite
Unsal, O., Yazici, O., Ozdemir, N., & Ozet, A. (2023). Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Annals of Medical Research, 30(8), 965–969. Retrieved from https://annalsmedres.org/index.php/aomr/article/view/4502
Section
Original Articles

Most read articles by the same author(s)